SUWNinactive

SUNWIN STEVIA INTERNATIONAL, INC.

Healthcare·Healthcare·Commercial

SUNWIN STEVIA INTERNATIONAL, INC. (SUWN): 1 pipeline candidate · ~15 mo cash runway. Updated within the last hour.

4.4/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway4.1

14.7 months

Financial Health0.0

D/E 3.54 · 316% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for SUNWIN STEVIA INTERNATIONAL, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$2.8M

Quarterly Burn

$1.4M

Runway

14.7 mo

Revenue

$7.4M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2027
Today~16 mo out
Catalyst within runway

Pipeline (1 candidate)

DrugPhase
steviosinApproved

Frequently asked questions

How many drug candidates are in SUNWIN STEVIA INTERNATIONAL, INC.'s pipeline?

SUNWIN STEVIA INTERNATIONAL, INC. (SUWN) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is SUNWIN STEVIA INTERNATIONAL, INC.'s lead drug candidate?

SUNWIN STEVIA INTERNATIONAL, INC.'s most advanced tracked candidate is steviosin (Approved) for medicinal use.

What is SUNWIN STEVIA INTERNATIONAL, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, SUNWIN STEVIA INTERNATIONAL, INC. has approximately 14.7 months of cash runway.

Get the full picture on SUNWIN STEVIA INTERNATIONAL, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.